Boris Kallmann

2.2k total citations · 1 hit paper
28 papers, 1.5k citations indexed

About

Boris Kallmann is a scholar working on Pathology and Forensic Medicine, Rheumatology and Oncology. According to data from OpenAlex, Boris Kallmann has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pathology and Forensic Medicine, 6 papers in Rheumatology and 5 papers in Oncology. Recurrent topics in Boris Kallmann's work include Multiple Sclerosis Research Studies (18 papers), Polyomavirus and related diseases (4 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Boris Kallmann is often cited by papers focused on Multiple Sclerosis Research Studies (18 papers), Polyomavirus and related diseases (4 papers) and Rheumatoid Arthritis Research and Therapies (4 papers). Boris Kallmann collaborates with scholars based in Germany, Switzerland and Italy. Boris Kallmann's co-authors include Peter Rieckmann, Klaus V. Toyka, Tania Kümpfel, M. Gottschalk, Peter Flachenecker, Oliver Grauer, Claudia Trenkwalder, Hubert Kolb, Carsten Lukas and Iris‐Katharina Penner and has published in prestigious journals such as Brain, Neurology and Diabetes.

In The Last Decade

Boris Kallmann

26 papers receiving 1.4k citations

Hit Papers

Fatigue in multiple scler... 2002 2026 2010 2018 2002 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters
    2002 505 citations Boris Kallmann, Peter Rieckmann et al. Multiple Sclerosis Journal profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Boris Kallmann 851 292 280 207 194 28 1.5k
Giancarlo Coghe 1.0k 1.2× 270 0.9× 284 1.0× 162 0.8× 128 0.7× 91 1.5k
Jan Boringa 1.6k 1.9× 464 1.6× 198 0.7× 268 1.3× 139 0.7× 15 2.3k
Florian Then Bergh 766 0.9× 545 1.9× 152 0.5× 306 1.5× 242 1.2× 60 1.6k
Merja Soilu‐Hänninen 1.2k 1.5× 372 1.3× 231 0.8× 600 2.9× 345 1.8× 72 2.2k
Bardia Nourbakhsh 877 1.0× 357 1.2× 164 0.6× 324 1.6× 268 1.4× 58 1.5k
Marta Radaelli 1.1k 1.3× 482 1.7× 111 0.4× 163 0.8× 199 1.0× 61 1.6k
Rainer Ehling 1.1k 1.3× 792 2.7× 98 0.3× 293 1.4× 177 0.9× 52 1.8k
Neeta Garg 1.3k 1.5× 395 1.4× 170 0.6× 91 0.4× 147 0.8× 23 1.7k
Francesco Saccà 656 0.8× 807 2.8× 159 0.6× 122 0.6× 843 4.3× 125 2.2k
Alessio Bratina 809 1.0× 247 0.8× 186 0.7× 129 0.6× 97 0.5× 38 1.1k

Countries citing papers authored by Boris Kallmann

Since Specialization
Citations

This map shows the geographic impact of Boris Kallmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Kallmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Kallmann more than expected).

Fields of papers citing papers by Boris Kallmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Kallmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Kallmann. The network helps show where Boris Kallmann may publish in the future.

Co-authorship network of co-authors of Boris Kallmann

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Kallmann. A scholar is included among the top collaborators of Boris Kallmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Kallmann. Boris Kallmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schwab, Matthias, Andrew Chan, Boris Kallmann, et al.. (2024). REBISTART: Adherence of Patients with Multiple Sclerosis to Treatment with Subcutaneous Interferon Beta in the Context of a Patient Support Program. Neurology and Therapy. 13(3). 641–653.
2.
Meuth, Sven G., Antonios Bayas, Boris Kallmann, et al.. (2022). Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4. Expert Opinion on Pharmacotherapy. 23(13). 1503–1510. 21 indexed citations
3.
Kallmann, Boris, et al.. (2021). Teriflunomide in relapsing-remitting multiple sclerosis: outcomes by age and pre-treatment status. Therapeutic Advances in Neurological Disorders. 14. 4203286676–4203286676. 9 indexed citations
4.
Kallmann, Boris, et al.. (2019). Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study. Therapeutic Advances in Neurological Disorders. 12. 1278056645–1278056645. 24 indexed citations
5.
Huhn, Konstantin, Antonios Bayas, Benedikt Frank, et al.. (2018). Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study. Journal of Neurology. 265(7). 1521–1527. 29 indexed citations
6.
7.
8.
Linker, Ralf A., Boris Kallmann, Christoph Kleinschnitz, et al.. (2015). „Time is brain“ bei der schubförmigen Multiplen Sklerose. Der Nervenarzt. 86(12). 1528–1537. 5 indexed citations
9.
Stangel, Martin, Iris‐Katharina Penner, Boris Kallmann, Carsten Lukas, & Bernd C. Kieseier. (2014). Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model. Therapeutic Advances in Neurological Disorders. 8(1). 3–13. 131 indexed citations
10.
Stangel, Martin, Iris‐Katharina Penner, Boris Kallmann, et al.. (2013). Multiple Sclerosis Decision Model (MSDM): Entwicklung eines Mehrfaktorenmodells zur Beurteilung des Therapie- und Krankheitsverlaufs bei schubförmiger Multipler Sklerose. Aktuelle Neurologie. 40(9). 486–493. 6 indexed citations
11.
Kallmann, Boris, Robert Mlynski, Karsten Nöckler, et al.. (2006). Isolation of Brucella melitensis from a patient with hearing loss. European Journal of Clinical Microbiology & Infectious Diseases. 25(1). 67–68. 11 indexed citations
12.
Bayas, Antonios, et al.. (2002). Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine. 19(2). 55–58. 39 indexed citations
13.
Martino, Gianvito, Luciano Adorini, Peter Rieckmann, et al.. (2002). Inflammation in multiple sclerosis: the good, the bad, and the complex. The Lancet Neurology. 1(8). 499–509. 108 indexed citations
14.
Hummel, Vera, Boris Kallmann, Sabine Wagner, et al.. (2001). Production of MMPs in Human Cerebral Endothelial Cells and Their Role in Shedding Adhesion Molecules. Journal of Neuropathology & Experimental Neurology. 60(4). 320–327. 65 indexed citations
15.
16.
Kallmann, Boris, E. F. Lampeter, Pejman Hanifi-Moghaddam, et al.. (1999). Cytokine secretion patterns in twins discordant for Type I diabetes. Diabetologia. 42(9). 1080–1085. 40 indexed citations
17.
Rieckmann, Peter, et al.. (1998). Correlation of soluble adhesion molecules in blood and cerebrospinal fluid with magnetic resonance imaging activity in patients with multiple sclerosis. Multiple Sclerosis Journal. 4(3). 178–182. 39 indexed citations
18.
Kallmann, Boris, Joachim Feldkamp, Jörg Bertrams, et al.. (1997). Systemic Bias of Cytokine Production Toward Cell-Mediated Immune Regulation in IDDM and Toward Humoral Immunity in Graves' Disease. Diabetes. 46(2). 237–243. 101 indexed citations
19.
Burkart, Volker, Yoichiro Imai, Boris Kallmann, & Hubert Kolb. (1992). Cyclosporin A protects pancreatic islet cells from nitric oxide‐dependent macrophage cytotoxicity. FEBS Letters. 313(1). 56–58. 22 indexed citations
20.
Kallmann, Boris, Volker Burkart, K D Kröncke, V. Kolb‐Bachofen, & Hubert Kolb. (1992). Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. Life Sciences. 51(9). 671–678. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giancarlo Coghe Breakdown of academic impact, for papers by Jan Boringa Breakdown of academic impact, for papers by Florian Then Bergh Breakdown of academic impact, for papers by Merja Soilu‐Hänninen Breakdown of academic impact, for papers by Bardia Nourbakhsh Breakdown of academic impact, for papers by Marta Radaelli Breakdown of academic impact, for papers by Rainer Ehling Breakdown of academic impact, for papers by Neeta Garg Breakdown of academic impact, for papers by Francesco Saccà Breakdown of academic impact, for papers by Alessio Bratina
Rankless by CCL
2026